Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is N/A as of Tuesday, October 6, 2026.
NET PROFIT MARGIN
N/A
Market Cap
$560.91M
Net Profit Margin
-435.21%
TTM Avg
0.14%
3Y Avg
-46.77%
5Y Avg
-98.73%
Market Cap
$564.46M
Net Profit Margin
40.49%
TTM Avg
5.54%
3Y Avg
-11349.71%
5Y Avg
-11563.54%
Market Cap
$570.25M
Net Profit Margin
-144.63%
TTM Avg
-132.38%
3Y Avg
-98.61%
5Y Avg
-109.15%
Market Cap
$543.14M
Net Profit Margin
-5256.80%
TTM Avg
-3099.51%
3Y Avg
-6775.80%
5Y Avg
-4603.58%
Market Cap
$541.90M
Net Profit Margin
-921.50%
TTM Avg
-767.53%
3Y Avg
-527.58%
5Y Avg
-706.89%
Market Cap
$535.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$537.90M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$536.12M
Net Profit Margin
0.56%
TTM Avg
-33.88%
3Y Avg
-929.83%
5Y Avg
-984.73%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $560.91M | -435.21% | 0.14% | -46.77% | -98.73% |
| CorMedix Inc. (CRMD)vs › | $564.46M | 40.49% | 5.54% | -11349.71% | -11563.54% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $570.25M | -144.63% | -132.38% | -98.61% | -109.15% |
| Shattuck Labs, Inc. (STTK)vs › | $543.14M | -5256.80% | -3099.51% | -6775.80% | -4603.58% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $541.90M | -921.50% | -767.53% | -527.58% | -706.89% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $535.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $537.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | 0.56% | -33.88% | -929.83% | -984.73% |
| ProKidney Corp. (PROK)vs › | $536.32M | -10599.76% | -44116.54% | -22058.27% | -14705.51% |
Operating Margin
N/A
Net Profit Margin
N/A
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
